Clinical Trials

Breast Neoplasms, Neoplasm Metastasis, Recurrence

NCT05340413 2026-03-16

RADIOLA

Phase 2 Completed

65 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01042379 2026-03-13

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT04090567 2026-03-05

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

60 enrolled

Phase 1 Active not recruiting

Breast Neoplasms

NCT03641755 2026-02-23

Olaparib + Sapacitabine in BRCA Mutant Breast Cancer

10 enrolled

Breast Neoplasms

NCT06829199 2026-02-19

MK-5890-003

Phase 2 Withdrawn

Phase 3 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02032823 2026-02-17

OlympiA

1,836 enrolled 20 charts 1 FDA

Breast Neoplasms

NCT04683679 2026-02-17

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

34 enrolled

302 enrolled 26 charts 1 FDA

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02000622 2026-02-13

OlympiAD

Phase 3 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT02624973 2026-02-12

PETREMAC

200 enrolled

Breast Neoplasms

NCT05238922 2026-02-10

Study of INCB123667 in Subjects With Advanced Solid Tumors

BreastGastrointestinalGynecologic

604 enrolled

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Digestive System Neoplasms

NCT03025035 2026-02-06

Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer

Phase 2 Completed

14 enrolled 8 charts

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT02734004 2026-01-29

MEDIOLA

264 enrolled 32 charts

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT04421963 2026-01-21

ROSY-O

Phase 3 Active not recruiting

185 enrolled

BreastGynecologic

Breast Neoplasms, Neoplasms, Ovarian Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Breast Neoplasms

NCT05203445 2026-01-12

A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer

23 enrolled

Breast Neoplasms

NCT03685331 2026-01-09

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

Phase 1 Completed

9 enrolled

Breast Neoplasms

NCT03344965 2026-01-05

Olaparib In Metastatic Breast Cancer

BreastClassical hematology

114 enrolled

Fanconi Anemia, Complementation Group D1, Breast Neoplasms

NCT04711824 2025-12-23

SOLARA

Phase 1/2 Recruiting

41 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT06545942 2025-12-23

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

BreastGastrointestinalGenitourinaryGynecologic

220 enrolled

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT03955640 2025-12-22

Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences

Phase 1 Terminated

3 enrolled

Phase 3 Active not recruiting

Breast Neoplasms

NCT06112379 2025-12-17

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

1,902 enrolled

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT02484404 2025-11-25

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

268 enrolled

BreastGastrointestinal

Breast Neoplasms, Colorectal Neoplasms

NCT02849496 2025-11-24

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

81 enrolled

Breast Neoplasms

NCT05900895 2025-11-20

PHOEBE

6 enrolled

Phase 1 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT03162627 2025-10-14

Selumetinib and Olaparib in Solid Tumors

90 enrolled

Breast Neoplasms

NCT02498613 2025-09-25

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

122 enrolled 16 charts

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT06245889 2025-09-23

NeoADAPT

30 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05932862 2025-09-05

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

BreastGastrointestinalGenitourinaryGynecologic

429 enrolled

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT07151911 2025-09-03

ROYAL

Recruiting

100 enrolled

Breast Neoplasms

NCT06488378 2025-08-22

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

20 enrolled

Breast Neoplasms

NCT03740893 2025-08-11

PHOENIX

119 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03568656 2025-08-08

Study to Evaluate CCS1477 in Advanced Tumours

Phase 1/2 Completed

220 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05498155 2025-06-10

OlympiaN

50 enrolled

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT03594396 2025-04-17

Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer

54 enrolled